-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: info
On December 12, Tengsheng Biopharmaceutical announced that it had received a notice from the US FDA to suspend the Phase I clinical study evaluating the safety of BRII-732 in healthy subjects
The FDA's suspension is mainly based on clinical studies related to Merck's drug islatravir (nucleoside reverse transcriptase translocation inhibitor)
On November 18, 2021, Merck announced the termination of Phase II IMAGINE-DR due to the observed decrease in total lymphocyte and CD4+ T cell counts in subjects randomized to receive islatravir + MK-8507 (a non-nucleoside reverse transcriptase inhibitor) (MK-8591-013) Research
Note: The original text has been deleted